Home | Publications | Research (R&D) | Clinical Trials place holder
place holder place holder

Clinical Trials

Opportunity for Molecular Imaging in Clinical Trials, The


Publication Date   March 2006
Publisher   IDC
Product Type   Report
Pages   39
ISBN Number   not applicable
Product Code   IDC017
Ask a question about this product?

Price £1,390.00

approximately: $2,073 | €1,656

Summary


This report examines the current and future applications of molecular imaging (MI) in clinical drug development and identifies areas in which technological advances will increase and broaden the clinical use of MI.

Noninvasive molecular measurements are becoming an integral part of rational decision making in the clinical evaluation of promising new drugs. MI techniques such as MRI, PET, CT, SPECT, ultrasound, and optical imaging are increasingly being used to connect evaluation of the molecular target in the lab to the metabolism of the compound in the body. MI offers a new level of understanding of how drug development candidates directly affect specific biological processes within the human body, providing insights early in the drug development process.

With increasing information, however, comes increasing complexity in both instrumentation and subsequent analysis. Through better knowledge-based drug development, MI is expected to make the pharmaceutical development more efficient and more productive.

Content


In This Report


Situation Overview

Introduction
Value Proposition for Molecular Imaging
Imaging Applications in Clinical Trials
Table: Application of Molecular Imaging in Clinical Trials
Table: Molecular Imaging Targets for Specific Therapeutic Areas
Table: Uses of Imaging Technologies for Clinical Compound Evaluation
Table: Benefits and Limitations of Specific Imaging Technologies
Imaging in the Clinical Environment
Magnetic Resonance Imaging (MRI or MR)
Functional MRI (fMRI)
Computed Tomography (CT, CAT, or Cat Scans)
Figure: Algorithmic Construction of Anatomical Images
Positron Emission Tomography (PET)
Single Photon Emission Computerized Tomography (SPECT)
Ultrasound Imaging
Optical Imaging
Fusion Modalities
Technology/Vendor Market Landscape
Figure: Preclinical Imaging Systems Vendor Landscape
Figure: Worldwide Imaging Market Share by Modality, 2005
Figure: Worldwide Imaging Revenue Share by Segment, 2005
Table: Molecular Imaging System Vendors in the Emerging Preclinical Area
Clinical Instrument Vendor Landscape
GE Healthcare
Siemens Medical Solutions
Philips Medical Systems
All Three
MI Contrast Agent Landscape
Table: Selected Vendors and Products of Molecular Imaging Contrast Agents
CRO Imaging Landscape
Table: Selected Imaging CROs
Government Efforts to Accelerate MI Adoption
MI and the NIH Roadmap for Medical Research
FDA and the Critical Path
NCI Imaging Efforts
Figure: NCI Cancer Imaging Programs Detailed Funding, FY96?FY03
Pharmaceutical Industry Adoption of MI in Clinical Trials
Factors Affecting the Wider Adoption of MI in Clinical Trials (and in the Hospital)
Imaging Technology Considerations
Contrast Agent Considerations
Infrastructure Considerations
Regulatory Considerations
Select New Technology Applications in Molecular Imaging

Future Outlook

Rapid Growth Expected in the Imaging Market
Table: U.S. Molecular Imaging Instrumentation Revenue, 2004-2009 ($M)
Table: Worldwide and U.S. Molecular Imaging Contrast Agent Sales Revenue, 2003-2009 ($M)

Essential Guidance

Actions to Consider
Specific Recommendations for Pharmaceutical and CRO R&D Management

Learn More

Related Research
Synopsis